H:/rec/Intrwovn/NRPortbl/DCC/REC/7739417_I.docx-30/04/2015 The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF2 1-associated disorders, including metabolic conditions.
申请公布号
AU2015202304(C1)
申请公布日期
2017.03.09
申请号
AU20150202304
申请日期
2015.05.01
申请人
Novartis AG
发明人
Boettcher, Brian R.;Caplan, Shari L.;Daniels, Douglas S.;Hamamatsu, Norio;Licht, Stuart;Weldon, Stephen Craig
